Heart failure (HF) with reduced ejection fraction (HFrEF)
Conditions
Brief summary
The percent change from baseline (pre-dose on Day 1) in plasma NT-proBNP for Doses 2 and 3 at Week 12
Detailed description
The percent change from baseline (pre-dose on Day 1) in urine and plasma cGMP at Week 12, The percent change from baseline (pre-dose on Day 1) in BNP at Week 12, The percent change from baseline (pre-dose on Day 1) in urine and plasma cGMP to NT-proBNP ratio at Week 12, The percent change from baseline (pre-dose on Day 1) in urine and plasma cGMP to BNP ratio at Week 12, The change from baseline (pre-dose on Day 1) in the KCCQ-23-CSS at Week 12 and the post-baseline NYHA classification at Week 12, The percent change from baseline (pre-dose on Day 1) in plasma NT proBNP at Week 12 for Dose 1
Interventions
Sponsors
Cardurion Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percent change from baseline (pre-dose on Day 1) in plasma NT-proBNP for Doses 2 and 3 at Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| The percent change from baseline (pre-dose on Day 1) in urine and plasma cGMP at Week 12, The percent change from baseline (pre-dose on Day 1) in BNP at Week 12, The percent change from baseline (pre-dose on Day 1) in urine and plasma cGMP to NT-proBNP ratio at Week 12, The percent change from baseline (pre-dose on Day 1) in urine and plasma cGMP to BNP ratio at Week 12, The change from baseline (pre-dose on Day 1) in the KCCQ-23-CSS at Week 12 and the post-baseline NYHA classification at Week 12, The percent change from baseline (pre-dose on Day 1) in plasma NT proBNP at Week 12 for Dose 1 | — |
Countries
Belgium, Bulgaria, Czechia, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, Poland, Slovakia, Spain
Outcome results
None listed